382 related articles for article (PubMed ID: 34780022)
1. Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction.
Elserafy AS; Reda A; Farag E; Mostafa T; Farag N; Elbahry A; Sanad O; Bendary A; Elkersh A; Attia I; Selim M; Khamis H; Issak ER
Clin Drug Investig; 2021 Dec; 41(12):1027-1036. PubMed ID: 34780022
[TBL] [Abstract][Full Text] [Related]
2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
[TBL] [Abstract][Full Text] [Related]
5. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
Aguilar-Gallardo JS; Correa A; Contreras JP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
[TBL] [Abstract][Full Text] [Related]
6. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
[TBL] [Abstract][Full Text] [Related]
7. Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US.
Talha KM; Butler J; Greene SJ; Aggarwal R; Anker SD; Claggett BL; Solomon SD; McMurray JJV; Vaduganathan M; Fonarow GC
JAMA Cardiol; 2023 Jan; 8(1):66-73. PubMed ID: 36334258
[TBL] [Abstract][Full Text] [Related]
8. SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction.
Silva-Cardoso J; Andrade A; Brito D; Ferreira J; Fonseca C; Peres M; Franco F; Moura B
Rev Port Cardiol (Engl Ed); 2021 Sep; 40(9):687-693. PubMed ID: 34503709
[TBL] [Abstract][Full Text] [Related]
9. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
[TBL] [Abstract][Full Text] [Related]
10. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
Starr JA; Pinner NA; Lisenby KM; Osmonson A
Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis.
Fukuta H; Hagiwara H; Kamiya T
Medicine (Baltimore); 2021 Dec; 100(51):e28448. PubMed ID: 34941199
[TBL] [Abstract][Full Text] [Related]
12. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
13. Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2023 Nov; 57(11):1291-1301. PubMed ID: 36800904
[TBL] [Abstract][Full Text] [Related]
14. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS
Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
[TBL] [Abstract][Full Text] [Related]
16. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
18. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure.
Vaduganathan M; Greene SJ; Zhang S; Solomon N; Chiswell K; Devore AD; Butler J; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Mcdermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Fonarow GC
J Card Fail; 2022 Apr; 28(4):554-563. PubMed ID: 34785402
[TBL] [Abstract][Full Text] [Related]
19. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
O'Meara E; Verma S
Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
Raschi E; Fadini GP; Diemberger I; Poluzzi E; De Ponti F
Expert Opin Pharmacother; 2021 Apr; 22(5):647-650. PubMed ID: 33141609
[No Abstract] [Full Text] [Related]
[Next] [New Search]
